Chimerix (NASDAQ:CMRX) Earns “Outperform” Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Chimerix (NASDAQ:CMRX) in a research report released on Tuesday,RTT News reports. Wedbush currently has a $7.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $6.00. Wedbush also issued estimates for Chimerix’s Q4 2025 earnings at $0.74 EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.89) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.58 EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Tuesday.

Chimerix Stock Performance

Shares of NASDAQ:CMRX opened at $5.17 on Tuesday. The stock has a market cap of $464.99 million, a PE ratio of -5.50 and a beta of 0.35. The business’s fifty day moving average price is $3.72 and its two-hundred day moving average price is $1.92. Chimerix has a one year low of $0.75 and a one year high of $5.53.

Insider Buying and Selling

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 20,760 shares of company stock valued at $91,175. Insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

Institutional investors and hedge funds have recently made changes to their positions in the company. Deerfield Management Company L.P. Series C acquired a new position in Chimerix in the fourth quarter valued at $13,124,000. Rosalind Advisors Inc. purchased a new position in shares of Chimerix in the 4th quarter worth about $10,614,000. Millennium Management LLC lifted its stake in shares of Chimerix by 6.8% in the 4th quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after purchasing an additional 161,795 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Chimerix by 1,318.5% during the 4th quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock worth $7,705,000 after purchasing an additional 2,057,864 shares during the period. Finally, Boxer Capital Management LLC acquired a new stake in Chimerix during the 4th quarter worth approximately $7,169,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.